Moderna (MRNA) Receivables (2017 - 2026)

Moderna (MRNA) has 10 years of Receivables data on file, last reported at $242.0 million in Q1 2026.

• On a quarterly basis, Receivables fell 19.87% year-over-year to $242.0 million in Q1 2026; TTM through Mar 2026 was $242.0 million, a 19.87% decrease from a year earlier, with the FY2025 full-year figure at $410.0 million, down 45.84% from the prior year.
• Receivables for Q1 2026 stood at $242.0 million, down from $410.0 million in the prior quarter.
• Over the last five years, Receivables for MRNA reached as high as $3.2 billion in Q1 2022 and fell as low as $108.0 million in Q2 2025.
• Historically, Receivables has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2023.
• Across the five-year window, Receivables sank 89.3% in 2023 and jumped 45.05% in 2024, its largest moves.
• Year by year, Receivables stood at $1.4 billion in 2022, then gained by 13.62% to $1.6 billion in 2023, then slumped by 53.93% to $757.0 million in 2024, then tumbled by 45.84% to $410.0 million in 2025, then slumped by 40.98% to $242.0 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $242.0 million in Q1 2026, $410.0 million in Q4 2025, and $2.1 billion in Q3 2025.